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1. Introduction 
The last decade has seen that several of the dominant and recessive forms of hypo- and 
hyperphosphatemic bone disease have received their molecular explanation. This has led to 
new insight into the pathophysiology of hypo- and hyperphosphatemic bone disease, as 
well as the understanding of a bone-kidney axis which operates integrated and in parallel 
with the classical parathyroid-kidney axis in the regulation of phosphorus content in the 
body. In addition, it has led to the recognition of a Janus face of some of the involved genes, 
showing both hyper- and hypofunction, dependent on the nature of the mutation.  In this 
book chapter, we will present an update on the emerging insight of monogenic hypo- and 
hyperphosphatemic disorders. 
2. Genetic mechanisms and pathophysiology 
Hypophosphatemia may lead to bone or dental disease resulting from decreased 
mineralization (calcification) of bone or dental matrix or osteoid. The simultaneous blood 
calcium levels will also influence the degree of mineralization. Hypophosphatemia leads to 
rickets in children or to osteomalacia in adults. In many of the hypophosphatemic 
conditions, there is also an impairment of renal activation of vitamin D, further aggravating 
disease. The mineralization of teeth can also be affected, and there are clinical forms where 
bone affection is minimal and the dental disorders dominate. 
Hyperphosphatemia may lead to increased mineralization of both bone and non-bone 
tissues (ectopic calcification) due to an increase in the body content of phosphorus. This 
results in tumoral calcinosis with calcification of muscles, skin and vessels. The monogenic 
forms affect the renal handling of phosphorus by various mechanisms resulting from 
inactivation or activation of the involved genes.  
With the advancement of genetic insight and the subsequent possibility to study subjects 
with mutations and a wide range of phenotypes, a broader phenotypic pattern is 
recognized. Consequently, we suggest the more appropriate terms of monogenic 
hypophosphatemia and monogenic hyperphosphatemia for these disorders, and that the 
specific disorders should be classified according to the affected gene, e.g. PHEX-
hypophosphatemia and FGF23-hyperphosphatemia (Table 1). 
We will now provide an overview of the genes directly implicated in monogenic phosphate 
balance disorders. Please refer to textbooks for a discussion of genes indirectly affecting 
phosphate balance (i.e.  genes leading to defective parathyroid gland development or 
disrupted PTH receptor function). 
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Gene Classical disease name Suggested new name 
PHEX 
X-linked dominant 
hypophosphatemic rickets 
PHEX-hypophosphatemia 
DMP1 
AR hypophosphatemic 
rickets 
DMP1-hypophosphatemia 
GALNT3 
Familial 
hyperphosphatemic 
tumoral calcinosis 
GALNT3-
hyperphosphatemia 
FGF23 
AD hypophosphatemic 
rickets 
FGF23- hypophosphatemia 
Familial 
hyperphosphatemic 
tumoral calcinosis 
FGF23- hyperphosphatemia 
FGFR1 
Osteogophonic dysplasia 
with hypophosphatemia 
FGFR1- hypophosphatemia 
KL 
Hypophosphatemic rickets 
and hyperparathyroidism 
KL-hypophosphatemia 
Hyperphosphatemic 
tumoral calcinosis 
KL-hyperphosphatemia 
SLC34A1 
Hypophosphatemic 
nefrolithiasis/ 
osteoporosis 
SLC34A1- 
hypophosphatemia 
SLC34A3 HHRH 
SLC34A1- 
hypophosphatemia 
SLC9A3R1 
Hypophosphatemic 
nephrolithiasis/ 
osteoporosis 
SLC9A3R1-
hypophosphatemia 
ENPP1 
AR hypophosphatemic 
rickets, type 2 
ENPP1-hypophosphatemia 
Table 1. Overview of genes directly implicated in monogenic phosphate balance disorders 
AR, autosomal recessive; AD autosomal dominant, HHRH, Hereditary hypophosphatemic 
rickets with hypercalciuria.  
2.1 PHEX 
The PHEX (Phosphate-regulating endopeptidase homolog, XB; MIM* 300550) gene consists 
of 22 exons (Sabbagh, Boileau et al. 2003) and was positionally cloned in 1995 (HYP 
Consortium 1995). This gene is encoding a transmembrane protein and belongs to the type II 
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integral membrane zinc-dependent endopeptidase family. The gene is expressed in a wide 
variety of tissues including the kidney with a higher expression in mature osteoblasts and 
odontoblasts.  The substrate for the gene product is not known, but the pathogenesis seems 
to involve phosphate regulating humoral factors, phosphatonins, where the fibroblast 
growth factor-23 (FGFR-23) is central (Jonsson, Zahradnik et al. 2003; Juppner 2007; Bastepe 
and Juppner 2008).  (See section 2.11 for a discussion on the physiological and 
pathophysiological mechanisms involved.) The protein is also believed to be involved in 
bone and dentin mineralization. Both the whole-body and bone-specific (osteocalcin-
promoted inactivation) knockout mouse model of PHEX as well as the spontaneous Hyp 
mouse model display increased bone production, increased levels of serum FGF23, 
decreased kidney membrane NPT2 and osteomalacia (Yuan, Takaiwa et al. 2008). Cell 
studies indicate mechanistic defects both during protein processing in the endoplasmic 
reticulum and cell membrane (Sabbagh, Boileau et al. 2001) and as abrogated catalytic 
activity (Sabbagh, Boileau et al. 2003). 
There are several mutations associated with PHEX-hypophosphatemia (see the PHEX 
mutation database: http://www.phexdb.mcgill.ca/) and most of the mutations are located 
in the region encoding the extracellular domain, but there are also examples of pathological 
mutations in the 5’UTR (Dixon, Christie et al. 1998) and 3’UTR (Ichikawa, Traxler et al. 2008) 
of the gene.  
 
 
Fig. 1. PHEX gene structure and the corresponding encoded regions. Adapted from 
(Sabbagh, Boileau et al. 2003). 
There is no clear genotype-phenotype correlation (Holm, Nelson et al. 2001). There is a 
slight dominance of familiar mutations (showing co-segregation with disease in a pedigree) 
to de novo mutations (sporadic) reported in literature (Holm, Nelson et al. 2001). The 
penetrance is high, although there are examples of non-penetrance (Gaucher, Walrant-
Debray et al. 2009). The expressivity varies (Brame, White et al. 2004).  
2.2 DMP1 
The DMP1 gene (dentin matrix acidic phosphoprotein 1; MIM* 600980) gene consists of 6 
exons on chromosome 4q21, and was first implicated in a phosphate balance disorder in 
2006 Lorenz-Depiereux, Bastepe et al. 2006). DMP1 is highly expressed in osteocytes, and is 
a member of the ‘SIBLING’ (small integrin binding ligand n-linked glycoprotein) family of 
non-collagenous extracellular matrix proteins involved in bone mineralization (Huq, Cross 
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et al. 2005). The DMP1 knockout model displays rickets and osteomalacia with isolated renal 
phosphate wasting associated with elevated FGF23 levels and normocalciuria (Feng, Ward 
et al. 2006).  In humans, homozygous or compound heterozygous mutations in DMP1 leads 
to hypophosphatemic rickets with elevated FGF23, isolated phosphate wasting, and no 
evidence of hypercalciuria. The exact relation between DMP1 and FGF23 levels is not 
known, but in vitro studies have shown that  vitamin D increases the expression of both 
(Farrow, Davis et al. 2009). 
There are only a few reported mutations in the literature (Feng, Ward et al. 2006; Lorenz-
Depiereux, Bastepe et al. 2006; Farrow, Davis et al. 2009; Koshida, Yamaguchi et al. 2010; 
Makitie, Pereira et al. 2010; Turan, Aydin et al. 2010), making DMP1 mutations a rare cause 
of hypophosphatemic rickets (Gaucher, Walrant-Debray et al. 2009). 
 
 
Fig. 2. DMP1 gene structure and the corresponding encoded regions. Based on (Huq, Cross 
et al. 2005). 
2.3 GALNT3  
The O-glycosylation of serine and threonine residues on many glycoproteins depend on 
enzymatic catalyzation of the reaction UDP-GalNAc + polypeptide-(Ser/Thr)-OH to 
GalNAc-alpha-O-Ser/Thr-polypeptide + UDP. GalNAcT3 is one of 24 members in the UDP-
GalNAc:polypeptide N-acetylgalactosaminyltransferase protein family involved in this 
process. 
GalNAcT3 is encoded by the GALNT3 gene (MIM *601756) on chromosome 2q24-q31, which 
contains 10 exons. GalNAcT3 is thought to protect FGF23 from proteolysis (Kato, Jeanneau 
et al. 2006) by O-glycosylation, and a deactivating mutation in GALNT3 will thus lead to 
increased breakdown of FGF23. Mutations in GALNT3 were the first to be associated with 
familial tumoral calcinosis (FTC) (Topaz, Shurman et al. 2004), and are also seen in the 
closely related disease, the hyperphosphatemic hyperostosis syndrome (HHS). These are the 
only diseases known to be caused by mutations in the family of UDP-GalNAc:polypeptide 
N-acetylgalactosaminyltransferases. Although the process of O-glycosylation is important in 
many tissues, mutations in GALNT3 lead to a very restricted phenotype with 
hyperphosphatemia, periarticular calcifications and hyperostosis. This is thought to be 
explained by functional redundancy of this protein family. In addition to the effects on bone 
and renal phosphate handling caused by altered FGF23 metabolism, mutations in GALNT3 
are also thought to have direct effect in the process of ectopic calcification in extraosseous 
tissues (Chefetz and Sprecher 2009). 
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2.4 FGF23 
The FGF23 gene (MIM*605380) on chromosome 12 is composed of 3 exons, and encodes a 
member of the fibroblast growth factor family. The protein product, FGF23, acts via its 
receptor FGFR1 (fibroblast growth factor receptor 1, see 2.5), but is also dependent on the 
co-receptor Klotho (-Klotho) to exert its functions (see below). Furthermore, FGF23 belongs 
to the FGF19 family where the two other family members, FGF19 and FGF21, (also binding 
to FGFR1) are dependent on ß -Klotho to exert their functions, illustrating the role of a co-
receptor to ensure tissue specificity and function (Kurosu, Choi et al. 2007). FGF23 exerts its 
physiological effects on the kidney by the downregulation of the CYP27B1 gene leading to a 
loss of compensatory increase in 1,25(OH)2vitamin D levels, and by the endocytosis of the 
type IIa and IIc Na/phosphate (Pi) cotransporters (Npt2a and Npt2c) from the renal 
proximal tubular brush border membrane.  
Heterozygous activating mutations in the cleavage site RXXR motif of exon 3 of FGF23, 
leads to stabilization and decreased degradation of the FGF23. The clinical phenotype is 
autosomal dominant hypophosphatemic rickets (Econs,  McEnery et al. 1997; 2000). 
Homozygous inactivating missense mutations in FGF23 lead to hyperphosphatemic familial 
tumoral calcinosis, due to decreased renal excretion of phosphate and increased renal α-
hydroxylation of vitamin D (Benet-Pages, Orlik et al. 2005; Ichikawa, Baujat et al. 2010). 
2.5 FGFR1 
The Fibroblast growth factor receptor 1 gene FGFR1 (MIM*136315) located on chromosome 
8p11 encodes a protein member of the FGFR (1-4) family, where the members are all 
receptor tyrosine kinases. FGFR1-3 are implicated in skeletal development, and various 
mutations in the corresponding genes are responsible for a number of skeletal dysplastic 
syndromes (Passos-Bueno, Wilcox et al. 1999).  There are several subclasses of FGFRs, 
depending on the number of immunoglobulin-like loops and splicing differences in the 
third loop. FGFR1C combines with Klotho (KL) to become the functional receptor for FGF23 
(Urakawa, Yamazaki et al. 2006). 
Mutations in the FGFR1C lead to constitutive activation of the receptor and subsequent 
downregulation of the expression of the sodium-phosphate co-transporters NaPiIIa and 
NaPiIIc, as well as the downregulation of the CYP27B1 gene leading to a loss of 
compensatory increase in 1,25(OH)2vitamin D levels (Shimada, Hasegawa et al. 2004).  
2.6 KL 
Klotho (KL) (MIM*604824) is located to chromosome 13q12, comprises 5 exons, and encodes 
the protein Klotho (also known as α-Klotho), which in mice is considered a hormone with 
anti-aging properties (Kurosu, Yamamoto et al. 2005). KL knockout mice will go through a 
rapid aging process, and have decreased insulin secretion and increased insulin sensitivity 
(Kuro-o, Matsumura et al. 1997), while overexpression of KL leads to a prolonged life span 
in mice (Kurosu, Yamamoto et al. 2005). In addition, Klotho has been associated with 
disturbances of phosphate metabolism, as it is an obligate co-receptor for the binding of 
FGF23 to FGFR1C. In humans, there are two KL transcripts; one encoding a membrane 
bound protein and one encoding a secreted protein. Human KL is expressed mainly in the 
kidney, and the secreted variant seems to dominate (Matsumura, Aizawa et al. 1998). Recent 
findings from mouse studies suggest that Klotho has endocrine, paracrine and autocrine 
effects independent of FGF23 (Hu, Shi et al. 2010).   
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Inactivating mutations will lead to familial hyperphosphatemic tumoral calcinosis, similar 
to the phenotypes seen in GALNT3-hyperphosphatemia and FGF23-hyperphosphatemia 
(Ichikawa, Imel et al. 2007).  
There is also one report of an activating translocation of the KL gene, leading to 
hypophosphatemic rickets with a phenotype similar to PHEX-hypophosphatemia but with 
additional distinctive dysmorphic features of the head (Brownstein, Adler et al. 2008). 
2.7 SLC34A1 
The solute carrier 34 (SLC34) gene family includes the three genes SLC34A1, SLC34A2 and 
SLC34A3, all encoding sodium/phosphate cotransporters. SLC34A2 encodes the intestinal 
NaPi-IIb, and will not be further discussed. SLC34A1 and SLC34A3 encode the two renal 
sodium/phosphate cotransporters, and the latter is described in 2.8 section. 
The SLC34A1 (MIM*182309) gene is expressed in the renal proximal tubule, and encodes the 
type IIa Na/Pi cotransporter (NaPi-IIa), which plays a central role in renal phosphate 
handling in various animal models. The expression of NaPi-IIa in the brush border 
membrane is regulated at the post translational level, by endocytosis and lysosomal 
degradation or microtubular recruitment (Tenenhouse 2005). Both PTH and FGF23 lead to 
increased endocytosis of NAPi-IIa, and thus decreased reabsorption of Pi from filtered 
urine, whereas hypophosphatemia and 1,25 dihydroxyvitamin D stimulate phosphate 
reabsorption (Tenenhouse 2005). There also seems to be a directly regulating effect of 
dietary Pi on Na/Pi cotransport in proximal tubules, and the existence of an intestinal-renal 
axis for phosphate regulation has been proposed [review: (Biber, Hernando et al. 2009)]. 
NaPi-IIa double knockout mice have hypophosphatemia, phosphaturia, elevated 1,25 
dihydroxyvitamin D with resulting hypercalcemia, hypercalcuria and 
nephrocalcinosis/nephrolithiasis (Beck, Karaplis et al. 1998). This phenotype resembles 
hereditary hypophosphatemic rickets with hypercalcuria (HHRH) seen in humans, which 
interestingly is not caused by mutations in SLCA34A1, but rather by mutations in SLC34A3 
(NaPi-IIc) (see 2.8). 
In man, a few cases have been described of heterozygous mutations in SLC34A1, leading to 
a syndrome of hypophosphatemia, osteoporosis and nephrolithiasis (Prie, Huart et al. 2002). 
2.8 SLC34A3 
The human SLC34A3 (MIM*609826) gene, consists of 13 exons on chromosome 9q34, and 
homozygous mutations in this gene  lead to hereditary hypophosphatemic rickets with 
hypercalciuria (HHRH) (Bergwitz, Roslin et al. 2006; Lorenz-Depiereux, Benet-Pages et al. 
2006). The phenotype of HHRH resembles that of NaPi-IIa knockout mice, but the patients also 
display rickets or osteomalacia. In animal models the type IIc Na/Pi cotransporter (NaPi-IIc) 
has been shown to play a more minor role in proximal tubular phosphate resorption than 
NaPi-IIa. The opposite might be the case in man (Amatschek, Haller et al. 2010). 
2.9 SLC9A3R1 
The SLC9A3R1 (MIM*604990) gene on chromosome 17 encodes the protein NHERF1 
(sodium/hydrogen exchanger regulatory factor 1), which plays a part in maintaining the 
cytoskeleton in polarized cells with microvilli, such as renal tubular cells. Three different 
mutations in SLC9A3R1 have recently been identified in 7 subjects with hypophosphatemia 
due to phosphaturia, nephrolithiasis and osteoporosis (Karim, Gerard et al. 2008). 
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2.10 ENPP1 
The ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) (MIM*173335) gene on 
chromosome 6q22-q23 comprises 23 exones and encodes a type II transmembrane 
glycoprotein ectoenzyme responsible for the generation of inorganic pyrophosphate (PPi). 
PPi is an inhibitor of hydroxyapatite crystal growth, and also suppress chondrogenesis. In 
mice, ENPP1 is expressed in plasma cells, on hepatocytes, renal tubules, salivary duct 
epithelium, epididymis, capillary endothelium in the brain, and chondrocytes (Harahap and 
Goding 1988). In man it has been shown that ENPP1 is expressed in liver, cartilage and 
bone, and is thought to regulate physiological mineralization processes and pathological 
chondrocalcinosis (Huang, Rosenbach et al. 1994). 
Homozygous mutations in ENPP1 are known to cause generalized arterial calcifications of 
infancy (GACI) (Rutsch, Vaingankar et al. 2001; Rutsch, Ruf et al. 2003). Recently, 
homozygous mutations in ENPP1 have been shown to cause autosomal recessive 
hypophosphataemic rickets (Levy-Litan, Hershkovitz et al. 2010). In some families, identical 
mutations cause GACI in some family members and hypophosphatemic rickets in other 
family members (Lorenz-Depiereux, Schnabel et al. 2010). Prolonged survival in GACI has 
been observed in subjects who have simultaneously displayed renal phosphate loss (Rutsch, 
Boyer et al. 2008).  
Mutations in ENPP1 have also been associated with susceptibility to insulin resistance and 
obesity (Goldfine, Maddux et al. 2008). 
2.11 An integrated model for the physiological and pathophysiological mechanisms in 
the renal phosphate regulation 
Figure 3 shows the integrated physiological and pathophysiological mechanisms in the 
renal phosphate regulation. The parathyroid-renal axis has been the traditional model 
explaining how PTH stimulates the renal tubular cells to phosphaturia as a negative 
feedback loop response to elevated phosphate levels (Figure 3A). In this model PTH acts via 
its receptor to block the sodium-phosphate co-transporters NaPiIIa and NaPiIIc encoded by 
the SLC34A1 and SLC34A3 genes, respectively. In addition, PTH stimulates the CYP27B1 
gene leading to a compensatory increase in 1,25(OH)2vitamin D levels as a negative 
feedback loop to reduced serum levels of 1,25(OH)2vitamin D and calcium.  There is, 
however, also a PTH-independent pathway where hormonal substances from bone, 
phosphatonins, stimulate the renal tubular cells to phosphaturia in a negative feedback 
response to elevated serum phosphate and 1,25(OH)2vitamin D levels. Recent emerging 
insight has laid the foundation for this model of a bone-kidney axis (Quarles 2003), where 
fibroblast growth factor 23 (FGF23) seems to be the central phosphatonin inhibiting 
phosphate reabsorption and hence inducing phosphaturia (Figure 3B). In contrast to PTH, 
FGF23 inhibits CYP27B1 gene leading to an absent compensatory increase in 
1,25(OH)2vitamin D levels, recognized by clinicians as inappropriate normal 
1,25(OH)2vitamin D levels. In the normal state PHEX and DMP1 gene products seem to 
inhibit FGF23 production, whereas the GALNT3 gene product seems to stimulate FGF23 
production. By interfering with the bone-kidney axis, increased FGF23 levels seem to play a 
central role in the pathogenesis of PHEX-hypophosphatemia (Jonsson, Zahradnik et al. 2003) 
(Figure 3C) and potentially also DMP1-hypophosphatemia (Lorenz-Depiereux, Bastepe et al. 
2006; Turan, Aydin et al. 2010) and FGF23- hypophosphatemia (Imel, Hui et al. 2007), but 
the mechanisms are still poorly known (Strom and Juppner 2008). It is also poorly known 
how increased FGF23 levels in FGF23- hyperphosphatemia and GALNT3- 
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hyperphosphatemia explain the opposite condition of hyperphosphatemia (Topaz, Shurman 
et al. 2004; Benet-Pages, Orlik et al. 2005). A current model postulates that mutations in 
PHEX lead to increased FGF23 production by cancelled PHEX-mediated inhibition of FGF23 
production (Figure 3 C). 
 
Fig. 3. Physiological and pathophysiological conditions in the phosphate regulation. For 
sake of clarity, only gene names are depicted and not the corresponding gene products. 
Adapted from (Bastepe and Juppner 2008; Strom and Juppner 2008). 
Both the parathyroid-renal axis and the bone-kidney axis seem to be negative feedback 
loops where increased serum phosphate levels compared to a biological set value leads to 
phosphaturia. These two axes are different with respect to 1,25(OH)2vitamin D: Whereas 
low 1,25(OH)2vitamin D levels stimulating 1,25(OH)2vitamin D activation is the major 
regulation in the parathyroid-renal axis, high 1,25(OH)2vitamin D levels inhibiting 
1,25(OH)2vitamin D activation is the major regulation in the bone-kidney axis. Recent work 
also points to interactions between these feedback loops where FGF23 inhibits PTH, 
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whereas PTH possibly stimulates FGF23 (Figure 3D). Mutations in genes encoding the 
sodium-phosphate co-transporters such as SLC34A1, SLC34A3 and SLC9A3R1 lead to 
increased phosphaturia but since the 1,25(OH)2vitamin D activation is unaffected, there is a 
normal compensatory increase in 1,25(OH)2vitamin D levels.  Whether gene mutations lead 
to hypophosphatemia or hyperphosphatemia is dependent on the location of the gene 
product in the pathways outlined above and whether the mutation is activating or 
inactivating the affected gene.  
3. Diagnostic considerations 
The diagnosis of monogenic hypo- or hyperphosphatemia requires the demonstration of 
affected phosphate balance in patients in which acquired causes of phosphate disturbance 
have been excluded. A family history of rickets, kidney stones, soft tissue calcification, bone 
deformities or recurrent fractures, as well as an indication of monogenic inheritance pattern 
is usually found, unless the patient seems to represent a sporadic case. In the case of 
hypophosphatemia, there is typically low plasma phosphate, low renal tubular reabsorption 
of phosphate (% TRP) and tubular threshold maximum for phosphate for glomerular 
filtration rate (TmP/GFR), raised alkaline phosphatase, normal PTH, and inappropriate and 
normal 25(OH) and 1,25(OH)2 vitamin D levels. Moreover, the urinary calcium excretion is 
normal, whereas X-ray changes may demonstrate rickets or osteomalacia. FGF23 levels are 
typically high, either due to overproduction or under-catabolism, and in children with 
rickets, the combined evaluation of FGF23 and PTH leads differential diagnosis in the 
direction of impaired phosphate homeostasis (high FGF23 and normal PTH) or altered 
metabolism of vitamin D, calcium or magnesium (low FGF23 and high PTH) (Alon 2010). In 
the case of hyperphosphatemia, there is usually high plasma phosphate, an inappropriate 
normal % TRP and TmP/GFR, a low or normal PTH and normal renal function. In some 
cases, the clinical picture and inheritance pattern will suggest a specific genetic diagnosis, 
and, in addition, the blood FGF23 levels and hypercalciuria may differentiate between 
different genetic disorders of phosphate balance, although the clinical role of blood FGF23 
levels is at present not fully elucidated. 
3.1 PHEX 
PHEX-hypophosphatemia (X-linked dominant) is usually a progressive disorder with a typical 
onset at the age when the child starts to walk. The most common clinical manifestations 
include genu varus, radiological rickets, short stature, bone pain, dental abscesses and 
calcification of tendons, ligaments and joint capsules with boys being more severely affected 
than girls and a wide variation between families (Econs, Samsa et al. 1994; Carpenter 1997; 
Bastepe and Juppner 2008). Some patients may even have craniosynosteosis and spinal 
stenosis. Many patients suffer from long lasting dental problems, particularly tooth decay and 
recurrent spontaneous dental abscesses that occur in the absence of a history of trauma or 
dental decay. Histological findings include high pulp horns, globular dentin, and defects of 
dentin and enamel. The primary teeth are most commonly affected, as the mineralization 
process starts in utero. Permanent teeth develop after birth, and adequate treatment improve 
development in some cases (Batra, Tejani et al. 2006). In children with rickets, a low serum 
phosphorus level, combined with high serum alkaline phosphatase and normal serum calcium 
is typical (Carpenter 1997). Urinary leakage of phosphate is demonstrated by low % TRP and 
TmP/GFR, whereas urinary calcium is normal. The PTH levels are usually normal or slightly 
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elevated, even before the onset of therapy. The 25(OH)vitamin D is normal, and there is no 
compensatory increase in 1,25(OH)2vitamin D levels due to defective renal activation of 
vitamin D, and, hence, no hypercalciuria. The FGF23 levels are increased (Jonsson, Zahradnik 
et al. 2003), and since the lower extremities are more severely affected than the other parts of 
the skeleton, radiographs of the knees and ankles will demonstrate the extent of rickets. The 
diagnosis of PHEX-hypophosphatemia is confirmed by genetic analysis. 
3.2 DMP1 
DMP1-hypophosphatemia (autosomal recessive) is usually a progressive disorder with a 
typical onset at the age when the child starts to walk. The condition is rarer than PHEX-
hypophosphatemia, but is phenotypically quite similar to PHEX- and FGF23- 
hypophosphatemie. There is no compensatory increase in 1,25(OH)2vitamin D levels due to 
defective renal activation of vitamin D and hence no hypercalciuria. The circulation levels of 
FGF23 are increased (Feng, Ward et al. 2006). The degree of skeletal abnormalities varies 
between families (Makitie, Pereira et al. 2010). Some patients also have dental affection, with 
hypomineralization, enlarged pulp chambers, and decrease in the dentin and enamel layers, 
which can cause dental abscesses and loss of teeth (Koshida, Yamaguchi et al. 2010; Turan, 
Aydin et al. 2010). 
3.3 GALNT3 
GALNT3-hyperphosphatemia is the result of biallelic mutation in the GALNT3-gene, and 
leads to typical tumoral calcinosis (TC) (Topaz, Shurman et al. 2004) or hyperostosis-
hyperphosphatemia syndrome (HHS). There are several mutations in the GALNT3 gene, 
and the same mutation can lead to TC in some patients and HHS in other (Ichikawa, Baujat 
et al. 2010). TC is characterized by ectopic calcifications in soft tissues and around large 
joints, recognized clinically as palpable masses and/or on radiography. Calcifications may 
also be found in the retina, in blood vessels, as testicular microlithiasis, and there might be 
dental abnormalities. HHC is characterized by hyperostosis of long bones, seen 
radiographically as cortical hyperostosis, diaphysitis and periosteal apposition. The 
biochemical findings in TC and HHC are similar, with elevated serum phosphate levels, 
increased or normal 1,25(OH)2vitamin D levels. The levels of serum calcium and 
parathyroid hormone are normal. Some authors suggest that TC and HHS are clinical 
variants of the same disease (Ichikawa, Baujat et al. 2010). 
3.4 FGF23 
FGF23-hypophosphatemia (autosomal dominant) shows a variable age at onset of 
disease.  
The expression of disease varies, and some children may have fracture tendency without 
skeletal deformities, whereas other children may have only temporary renal phosphate loss 
(Econs and McEnery 1997). Tooth abscesses and loss also occurs (Imel, Hui et al. 2007). 
FGF23-hyperphosphatemia (autosomal recessive) shows typical tumoral calcinosis , or more 
rarely the hyperostosis-hyperphosphatemia syndrome (Benet-Pages, Orlik et al. 2005). 
3.5 FGFR1 
FGFR1R-hypophosphatemia is characterized by osteoglophonic dysplasia and can be 
associated with hypophosphatemia (Farrow, Davis et al. 2006). Clinical features are skeletal 
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abnormalities leading to dwarfism and facial abnormalities similar to achondroplasia. There 
is often failure of tooth eruption, and mandibular malformations. Patients may also have 
various degrees of craniosynostosis (White, Cabral et al. 2005). 
3.6 KL 
To date only one case of KL-hypophosphatemia has been described in the literature 
(Brownstein, Adler et al. 2008). A 1-year old girl suffered from poor linear growth and 
increasing head size. She had clinical and radiological signs of rickets, 
hypophosphatemia, renal phosphate wasting and elevated levels of parathyroid hormone 
and alkaline phosphatase. A balanced translocation between chromosomes 9 and 13 was 
detected (t(9,13)(q21.13;q13.1)). This translocation had led to upregulation of KL-
transcription. After a few years she demonstrated dysmorphic features of the face, and 
also an Arnold-Chiari 1 malformation (Brownstein, Adler et al. 2008). Dental affection has 
not been described. 
KL-hyperphosphatemia has also been described in only one report (Ichikawa, Imel et al. 
2007). A 13 year old girl presented with severe calcifications in soft tissues and in the 
vasculature, including the dura and the carotid arteries. In addition to hyperphosphatemia 
and hypercalcemia, she presented with hyperparathyroidism and elevated levels of FGF23. 
She had no signs of premature aging, which is seen in KL knockout mice. Dental affection 
has not been described. 
3.7 SLC34A1 and SLC34A3 
In SLC34A1- and SLC34A3-hypophosphatemia, there is hypophosphatemic rickets with 
hypercalciuria without other tubular defects (Tieder, Modai et al. 1985). The inheritance 
pattern is autosomal recessive. Since there is normal renal activation of vitamin D (in 
contrast to PHEX-hypophosphatemia and DMP1-hypophosphatemia), hypophosphatemia 
leads to a normal compensatory increase in 1,25(OH)2vitamin D levels and increased 
absorption of calcium and phosphate from the gut.  
3.8 SLC9A3R1 
A total of 7 cases of SLC9A3R1-hypophosphatemia (hypophosphatemia, 
nephrolithiasis/osteoporosis) have been described to date (Karim, Gerard et al. 2008). All 
patients were adults, and had either nephrolithiasis and/or bone demineralization 
combined with hypophosphatemia and hyperphosphaturia. 1,25 (OH)2 vitamin D levels 
were either elevated or in the upper normal range. Dental affection has not been described. 
3.9 ENPP1 
ENPP1-hypophosphatemia (autosomal recessive) has a variable age at onset and a variable 
phenotype including Generalized Arterial Calcification of Infancy (GACI). Also there seems 
to be phenotypic variation within the same family among affected subjects carrying the 
same mutation. Whereas the classic presentation is that of severe arterial calcification 
leading to death in infancy, some patients have renal phosphate wasting and 
hypophosphatemia. This phosphate loss seems to attenuate the tendency of arterial 
calcifications, and is associated with prolonged survival (Lorenz-Depiereux, Schnabel et al. 
2010).  
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4. Management principles 
4.1 Hypophosphatemia 
Hypophosphatemic rickets is in childhood usually treated with elementary phosphorus at 
doses preferentially between 30 and 60 (100) mg/kg bodyweight and 24 hours, usually 
divided by 4-6 doses, whereas the deficient 1,25(OH)2vitamin D production is treated with 
active vitamin D, e.g. alphacalcidol or calcitriol in doses of 20 to 70 ng/kg bodyweight and 
24 hours, usually divided by 2 doses. It should, however, be emphasized that the dosage 
ranges for both phosphate and active vitamin D are wide, dependent on the severity of the 
disease, the compliance and the occurrence of complications. In SLC34A1- and SLC34A3-
hypophosphatemia, activation of vitamin D is normal, and, consequently, there is no need 
for treatment with vitamin D.  
It is important to adjust the drug doses individually and bear in mind that insufficient doses 
of elementary phosphorus and vitamin D may fail to prevent or correct skeletal deformities 
(rickets, osteomalacia) and can lead to growth retardation. On the other hand, excessive 
doses may lead to nephrocalcinosis (high phosphate doses), as well as hypercalciuria and 
hypercalcemia (high vitamin D levels). Secondary (and even tertiary) hyperparathyroidism 
is seen in patients with insufficient doses of vitamin D or excessive doses of phosphorus. We 
recommend aiming at normal levels of PTH, which in severe cases may be obtained by 
adding the calcimimetic drug cinacalcet to the treatment (Raeder, Bjerknes et al. 2008).  
Close monitoring is necessary to balance the effects of phosphorus supplement and active 
vitamin D. Growth, serum calcium, phosphorus, alkaline phosphatase, PTH, as well as 
urinary calcium/creatinine ratio should be determined every 3-6 months, and X-rays of 
ankles, knees and wrist should be taken yearly. Renal ultrasound should be obtained yearly 
to assess nephrocalcinosis.  
Supplementary treatment with growth hormone is currently not recommended for the 
growth retardation caused by hypophosphatemia (Huiming and Chaomin 2005), but may be 
warranted in selected cases. Corrective osteotomies are seldom necessary in childhood, and 
it should always be deferred until the rickets has healed. Future therapeutic possibilities 
may include direct targeting of blood FGF23 levels. 
4.2 Hyperphosphatemia 
Patients with hyperphosphatemia due to monogenic phosphate balance disorders, i.e. 
GALNT3-hyperphosphatemia, FGF23-hyperphosphatemia and KL-hyperphosphatemia, 
develop ectopic and vascular calcifications. Combined use of intestinal phosphate binders 
and the carbonic anhydrase inhibitor acetazolamide has been reported to lower serum 
phosphorus levels and reduce tumoral masses in some patients (Garringer, Fisher et al. 
2006). However, other reports suggest that neither medical nor surgical treatment seems to 
be effective in controlling ectopic calcifications in these conditions (Carmichael, Bynum et al. 
2009). Future therapeutic possibilities may include direct targeting of blood FGF23 levels. 
4.3 Genetic diagnostics and predictive testing 
Identification of a specific mutation has important therapeutic and prognostic implications 
and tailored follow-up as outlined above.  Distinction between PHEX-hypophosphatemia 
and DMP1-hypophosphatemia can be done clinically based on the inheritance pattern, but 
in some cases there is an ambiguous inheritance pattern (Figure 4) and a genetic test will 
resolve this ambiguity. 
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Fig. 4. An example of ambiguous inheritance pattern. Note that in this case, the pattern is 
compatible both with an X-linked disorder (i.e. PHEX-hypophosphatemia) and an AR 
disorder (i.e. DMP1-hypophosphatemia). 
Monogenic phosphate balance disorders warrant genetic counseling, because of the known 
inheritance pattern and the high penetrance. This is also the case for novel gene variants 
where it is necessary to establish evidence for causality based on co-segregation studies and 
prediction tools (such as Polyphen http://genetics.bwh.harvard.edu/pph/)). Predictive 
genetic testing is less straightforward, and the legal regulations vary in different countries. 
Communicating genetic information can be difficult and it is important to take into account 
how well the individual understands both genetics in general and the disorder itself and the 
consequences of potentially diagnosing other family subjects. The basic fact that there is a 
25% or 50% probability for a child to carry the family’s mutation should be conveyed to the 
parents. In addition, the probability for the development of the disorder in the presence of a 
mutation (i.e. the penetrance) is not always 100%. The variable and in some cases 
unpredictable age of onset of some of the disorders should also be discussed. By increasing 
knowledge of the clinical spectrum of mutations, novel expected manifestations need to be 
discussed with the patient. A system for follow-up is required for children without a 
phenotype but with affected family members and where parents still request that their child 
be tested. This follow-up may include periodic testing for hypophosphatemia, with a 
frequency dependent on age and the suspected condition. 
5. Research perspectives 
We have established a national database of patients with hypophospahtemic bone disorder in 
order to study phenotype-genotype correlation in this disease and to be able to explore novel 
pathophysiologic pathways based on insight obtained from studies of families with no 
previously known genetic cause of monogenic hypophosphatemic bone disorder. We believe 
that a new classification of disease based on genetic etiology instead of clinical criteria may 
facilitate the finding of new phenotypes since it will facilitate the study of unobserved 
phenotypes, both in the patients and in their presumably unaffected relatives carrying 
mutations. In addition, it is possible that emerging new treatment options may vary based on 
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the genetic diagnosis which warrants studies of associations between gene variants and 
therapeutic effects. Future studies of monogenic phosphate balance disorders will probably 
continue to include genomewide studies of families with genetically unexplained phosphate 
balance disorders. Animal and cell studies will probably also continue to contribute to the 
understanding of disease mechanism, and, in particular, the use of induced pluripotent stem 
cells (iPS) seems to be a promising new tool in the mechanistic and therapeutic studies 
(Rosenzweig 2010) as well as the use of small molecule screens in the search for new 
therapeutic options in monogenic disease (Shaw, Blodgett et al. 2011) .  
6. Conclusion 
As we have discussed in this book chapter, several of the dominant and recessive forms of 
hypo- and hyperphosphatemic bone disease have received their molecular explanation 
leading to new insight into the pathophysiology of hypo- and hyperphosphatemic bone 
disease. The major advancement in pathophysiological understanding has come from the 
understanding of a bone-kidney axis where the central bone phosphatonin FGF23 acts on 
FGFR1-receptors in the kidneys to promote phosphaturia and from the understanding of all 
the factors converging on this axis. In fact, this axis ties together the known monogenic 
forms of renal phosphate disorders. In addition, the understanding of the genetics and 
pathophysiology of these disorders has led to the recognition of the two faces of some of the 
involved genes, showing both hyper- and hypofunction, dependent on the nature of the 
mutation, which is in particular the case for mutations affecting the KL and FGF23 genes.  
We recommend the use of a genetic-oriented classification instead of the traditional disease-
oriented classification since we believe that this will facilitate a broader understanding of the 
phenotype of monogenic phosphate balance disorders. Whereas increased molecular 
understanding has led to a more precise diagnosis, it has not yet led to new established 
treatment. We believe, however, that the molecular understanding will indeed facilitate the 
development of new treatment options with the use of the powerful tools including iPS cells 
and small molecular screens. 
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